CNTXT
16.11.2023 11:01:35 CET | Business Wire | Press release
Following yesterday's successful launch of Google Cloud's new region in the Kingdom of Saudi Arabia, CNTXT has been appointed as Google Cloud’s exclusive reseller for local organizations and multinationals purchasing Google Cloud Platform Services on a standalone basis through their Saudi-based entities.
Underpinned by a robust collaboration between CNTXT and Google Cloud in the Kingdom, CNTXT will also support Google Cloud partners in the Kingdom to deliver cloud professional and managed services. One of the key focus areas for CNTXT will be accelerating the journey of local Saudi-based independent software vendors (ISVs) to the cloud and the Google Cloud Marketplace, fostering more software development and deployment.
Additionally, CNTXT is offering support for workloads hosted in the Kingdom of Saudi Arabia through its strategic collaboration with the Saudi Information Technology Company (SITE) and Fortanix. This landmark partnership is designed to provide Google Cloud customers with security solutions leveraging the new in-country Google Cloud region.
Google Cloud is the new way to cloud, and shared fate is the new way to operate, manage risk, and succeed in shared responsibility. This initiative underscores Google Cloud and CNTXT's joint commitment to delivering solutions that help Saudi businesses meet data security and compliance requirements for enterprises.
Established last year as a joint venture between Aramco and Cognite, CNTXT has evolved into a leading digital transformation company headquartered in Riyadh. This partnership with Google Cloud further solidifies CNTXT’s commitment to leading the digital transformation change in the Kingdom.
Nabil Al-Nuaim, Aramco Senior Vice President of Digital & Information Technology, stated: “When it comes to spearheading the digital transformation across the Kingdom’s public and private sectors, CNTXT plays a significant and pivotal role in collaboration with its esteemed partners, which is undeniably of paramount importance. Their unwavering dedication to empower and upskill local talent aligns seamlessly with our visionary pursuit of a digitally empowered Saudi Arabia. This marks the beginning of a transformative era, a magnificent milestone in the Kingdom's digital landscape that leads to unprecedented progress and endless possibilities."
Abdul Rahman Al Thehaiban, Managing Director, Middle East, Turkey and Africa, Google Cloud, said: "Google Cloud stands as one of the pioneering hyperscalers to launch a cloud region in the Kingdom of Saudi Arabia, a clear manifestation of our commitment to leading the digital evolution of the region.”
Bader Al Madi, Saudi Arabia Country Manager, Google Cloud, said: “Our partnership with CNTXT will support Google Cloud’s plans to empower every business and every person with access to the latest cloud technologies in the Kingdom of Saudi Arabia. We look forward to working hand in hand with CNTXT together with all our partners to pave the path for the Kingdom’s digital transformation and collaborate on helping businesses of all sizes in the country accelerate their digital transformation, optimize their operations, reduce costs and deliver exceptional customer experiences.”
CNTXT CEO, Abdullah Jarwan, remarked, "We are honored to become a leading cloud and digital transformation company in the Kingdom. Our collaboration with Google Cloud will empower us to work on accelerating the digital transformation of public and private sectors in Saudi Arabia. We are committed to building a brighter, more technologically advanced future for the Kingdom."
About CNTXT: CNTXT, a joint venture between Saudi Aramco and Cognite, is a leading digital transformation company headquartered in Riyadh, Saudi Arabia. With a mission to empower organizations through technology and innovation, CNTXT leverages strategic partnerships and a network of resellers to accelerate digital transformation across public and private sectors in the Kingdom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116735194/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom